Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 1, 2011, Pages 23-29

  Lu, Xujin ^a   Xiao, Baiming ^a   Lo, Lili ^a   Bolgar, Mark S ^a   Lloyd, David K ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Comparator drug; Erlotinib; Hard gelatin capsule; In vitro dissolution; Overencapsulated formulation; UV fiber optic

Indexed keywords

DODECYL SULFATE SODIUM; ERLOTINIB; GELATIN; HYDROCHLORIC ACID; PEPSIN A;

ARTICLE; CROSS LINKING; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; ENZYME ACTIVITY; FIBER OPTICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SPECTROMETRY; TABLET FORMULATION; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-LINKING REAGENTS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; FIBER OPTIC TECHNOLOGY; GELATIN; QUINAZOLINES; SOLUBILITY; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS;

EID: 79958035498     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.04.026     Document Type: Article

References (20)

1. Myers R.G., Cratty C.M. Blinding clinical supplies utilizing overencapsulation. Pharm. Eng. 2003, 23:1-5.
2. Huynh-Ba K.C., Aubry A.-F. Analytical development strategies for comparator products. Am. Pharm. Rev. 2003, 6:92-97.
3. US FDA Dissolution Database, records since 2004. http://www.fda.gov/Drugs/InformationOnDrugs/ucm135742.htm.
4. Digenis G.A., Gold T.B., Shah V.P. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J. Pharm. Sci. 1994, 83:915-921.
5. Singh S., Rao K.V.R., Venugopal K., Manikandan R. Alteration in dissolution characteristics of gelatin-containing formulations. Pharm. Technol. 2002, 26:36-58.
6. Brown J., Madit N., Cole E.T., Wilding I.R., Cade D. The effect of cross-linking on the in vivo disintegration of hard gelatin capsules. Pharm. Technol. 1998, 15:1026-1030.
7. Digenis G.A., Sandefer E.P., Page R.C., Doll W.J., Gold T.B., Darwazeh N.B. Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture. Pharm. Technol. 2000, 17:572-582.
8. The United States Pharmacopeia Dissolution, General Chapter<711>, USP 32-NF 27 2009, USP, Rockville, MD, USA, p. 263.
9. Marchais H., Cayzeele G., Legendre J.-Y., Skiba M., Arnaud P. Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release. Eur. J. Pharm. Sci. 2003, 19:129-132.
10. Pennings F.H., Kwee B.L.S., Vromans H. Influence of enzymes and surfactants on the disintegration behavior of cross-linked hard gelatin capsules during dissolution. Drug Dev. Ind. Pharm. 2006, 32:33-37.
11. Zhao F., Malayev V., Rao V., Hussain M. Effect of sodium lauryl sulfate in dissolution media on dissolution of hard gelatin capsule shells. Pharm. Res. 2004, 21:144-148.
12. Cohen M.H., Jonson J.R., Chen Y.F., Sridhar R., Pazdur R. FDA drug approval summary: erlotinib (Tarceva®) tablets. Oncologist 2005, 10:461-466.
13. Pujeri S.S., Khader A.M.A., Seetharamappa J. Validated stability-indicating chromatographic method for the assay of erlotinib active pharmaceutical ingredient. Anal. Lett. 2009, 42:1855-1867.
14. Tien Y.-C., Su C.-S., Lien L.-H., Chen Y.-P. Recrystallization of erlotinib hydrochloride and fulvestrant using supercritical antisolvent process. J. Supercrit. Fluid 2010, 55:292-299.
15. Lu X., Lozano R., Shah P. In situ dissolution testing using different UV fiber optic probes and instruments. Dis. Technol. 2003, 10:6-15.
16. Wiberg K.H., Hultin U.-K. Multivariate chemometric approach to fiber-optic dissolution testing. Anal. Chem. 2006, 78:5076-5085.
17. Bijlani V., Younayel D., Katpally S., Chukwumezie B.N., Adeyeye M.C. Monitoring ibuprofen release from multiparticulates: in situ fiber-optic technique versus the HPLC method: a technical note. AAPS PharmSciTech 2007, 8:E9-E12. 10.1208/pt0803052.
18. Mirza T., Liu Q., Vivilecchia R., Joshi Y. Comprehensive validation scheme for in situ fiber optic dissolution method for pharmaceutical drug product testing. J. Pharm. Sci. 2009, 98:1086-1094.
19. The United States Pharmacopeia The Dissolution Procedure: Development and Validation, General Chapter<1092>, USP 32-NF 27 2009, USP, Rockville, MD, USA, p. 599.
20. International Conference on Harmonization, Validation of Analytical Procedures: Text and Methodology Q2 (R1), Harmonized Tripartite Guideline Q2A 1994, 3.